CA2239360A1 - G-csf analog compositions and methods - Google Patents

G-csf analog compositions and methods

Info

Publication number
CA2239360A1
CA2239360A1 CA002239360A CA2239360A CA2239360A1 CA 2239360 A1 CA2239360 A1 CA 2239360A1 CA 002239360 A CA002239360 A CA 002239360A CA 2239360 A CA2239360 A CA 2239360A CA 2239360 A1 CA2239360 A1 CA 2239360A1
Authority
CA
Canada
Prior art keywords
analogs
csf
methods
another aspect
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002239360A
Other languages
French (fr)
Other versions
CA2239360C (en
Inventor
Timothy D. Osslund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc.
Timothy D. Osslund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2239360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc., Timothy D. Osslund filed Critical Amgen Inc.
Priority to CA2381489A priority Critical patent/CA2381489C/en
Publication of CA2239360A1 publication Critical patent/CA2239360A1/en
Application granted granted Critical
Publication of CA2239360C publication Critical patent/CA2239360C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Provided herein are granulocyte colony stimulating factor ("G-CSF") analogs, compositions containing such analogs, and related compositions. In another aspect, provided herein are nucleic acids encoding the present analogs or related nucleic acids, related host cells and vectors. In yet another aspect, provided herein are computer programs and apparatuses for expressing the three dimensional structure of G-CSF and analogs thereof. In another aspect, provided herein are methods for rationally designing G-CSF analogs and related compositions. In yet another aspect, provided herein are methods for treatment using the present G-CSF analogs.
CA002239360A 1993-01-28 1994-01-25 G-csf analog compositions and methods Expired - Lifetime CA2239360C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2381489A CA2381489C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/010,099 1993-01-28
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA002153896A CA2153896C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002153896A Division CA2153896C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2381489A Division CA2381489C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Publications (2)

Publication Number Publication Date
CA2239360A1 true CA2239360A1 (en) 1994-08-04
CA2239360C CA2239360C (en) 2002-07-16

Family

ID=21743861

Family Applications (4)

Application Number Title Priority Date Filing Date
CA002239360A Expired - Lifetime CA2239360C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
CA2711007A Expired - Lifetime CA2711007C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
CA002153896A Expired - Lifetime CA2153896C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
CA2381489A Expired - Lifetime CA2381489C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA2711007A Expired - Lifetime CA2711007C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
CA002153896A Expired - Lifetime CA2153896C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
CA2381489A Expired - Lifetime CA2381489C (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods

Country Status (22)

Country Link
US (6) US5581476A (en)
EP (8) EP0612846B1 (en)
JP (7) JPH08506018A (en)
KR (2) KR100390338B1 (en)
CN (3) CN1118572C (en)
AT (2) ATE195552T1 (en)
AU (2) AU697451B2 (en)
CA (4) CA2239360C (en)
DE (1) DE69425516T2 (en)
DK (3) DK1482046T3 (en)
ES (3) ES2422269T3 (en)
FI (2) FI120769B (en)
GR (1) GR3034745T3 (en)
HK (2) HK1009288A1 (en)
IL (6) IL124112A (en)
LU (1) LU92265I2 (en)
LV (1) LV12642B (en)
NO (3) NO952974L (en)
NZ (5) NZ261765A (en)
PT (3) PT612846E (en)
WO (1) WO1994017185A1 (en)
ZA (1) ZA94568B (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
DE68925966T2 (en) * 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (en) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Quantification of PEGylated human granulocyte colony-stimulating factor
US6273598B1 (en) * 1996-01-22 2001-08-14 Creative Biomolecules, Inc. Computer system and methods for producing morphogen analogs of human OP-1
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (en) * 1997-11-19 2001-02-14 蒋永平 Colony stimulating factor for recombination of human granulocytes and medicinal composition thereof
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
KR100479790B1 (en) * 1998-04-30 2005-03-30 타녹스 인코퍼레이티드 G-CSF receptor agonist antibodies and screening method therefor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6627186B1 (en) 1999-01-06 2003-09-30 Xencor Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
PT1157037E (en) * 1999-01-29 2003-12-31 Hoffmann La Roche GCSF CONJUGATES
US6500418B1 (en) 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (en) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk Crystal and structural coordinate of protein complex, and use of structural coordinate
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
MXPA01009999A (en) * 1999-04-06 2003-07-14 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth.
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
CA2372526A1 (en) * 1999-05-10 2000-11-16 Michael D. Wyrsta Methods and compositions for controlled polypeptide synthesis
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
NZ517184A (en) * 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
ES2327606T3 (en) * 2000-01-10 2009-11-02 Maxygen Holdings Ltd CONJUGATES OF G-CSF.
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
ATE258884T1 (en) * 2000-06-16 2004-02-15 Vsi Holding As CONTAINER WITH FOLDABLE WALLS
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US7792645B2 (en) * 2000-08-30 2010-09-07 The Salk Institute For Biological Studies Three-dimensional structure of chalcone isomerase and methods of use thereof
US20040254351A1 (en) * 2000-09-07 2004-12-16 Beals John Michael Hyperglycosylated polypeptides
DK1317537T3 (en) * 2000-09-08 2007-04-30 Massachusetts Inst Technology Compositions and Methods with G-CSF Analogs
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
WO2002073373A2 (en) * 2001-03-12 2002-09-19 Board Of Regents, University Of Texas System Ensemble-based strategy for the design of protein pharmaceuticals
DE10112825A1 (en) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
JP4444652B2 (en) * 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド G-CSF conjugate
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1522037A2 (en) * 2002-05-23 2005-04-13 Board Of Regents The University Of Texas System Predicting the significance of single nucleotide polymorphisms (snps) using ensemble-based structural energetics
US20040007672A1 (en) * 2002-07-10 2004-01-15 Delucas Lawrence J. Method for distinguishing between biomolecule and non-biomolecule crystals
ATE466085T1 (en) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
DE10242076A1 (en) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever
BR0314227A (en) * 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Hydroxyalkyl Starch Derivatives
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1549350B1 (en) * 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmaceutically active oligosaccharide conjugates
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
BRPI0412671A (en) * 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugates of a polymer and a protein linked by an oxime linking group
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
DK2441465T3 (en) * 2003-10-24 2014-04-14 Nora Therapeutics Inc Preparations and Methods for a Healthy Pregnancy
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
AR048918A1 (en) * 2004-03-11 2006-06-14 Fresenius Kabi De Gmbh CONJUGADOS DE ALMIDON DE HIDROXIETILO Y ERITROPOYETINA
JP2008507294A (en) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド Method for improved protein expression by strain genetic manipulation
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
WO2006063300A2 (en) * 2004-12-10 2006-06-15 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor
US7790174B2 (en) 2004-12-23 2010-09-07 Merck Serono Sa G-CSF polypeptides and uses thereof
JP4951527B2 (en) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー GlycoPEGylated granulocyte colony stimulating factor
KR100657749B1 (en) * 2005-04-13 2006-12-20 씨제이 주식회사 Human Granulocyte-Colony Stimulating Factor Isoform and Composition thereof
WO2006128460A2 (en) * 2005-06-01 2006-12-07 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
KR100694994B1 (en) * 2005-06-13 2007-03-14 씨제이 주식회사 Human Granulocyte-Colony Stimulating Factor Isoforms
KR100735784B1 (en) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
JP5509444B2 (en) * 2005-08-15 2014-06-04 ファレス ファーマシューティカル リサーチ エヌ．ブイ． Crystalline form of astaxanthin
US8017315B2 (en) * 2005-08-22 2011-09-13 Dana Farber Cancer Institute, Inc. Mitochondrial localization of MUC1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2008111996A2 (en) * 2006-07-20 2008-09-18 Dana-Farber Cancer Institute, Inc. Muc1-ikb kinase complexes and their activities
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
JP4375412B2 (en) * 2007-02-19 2009-12-02 株式会社デンソー Evaporator unit
BRPI0810120A2 (en) 2007-04-27 2014-11-11 Dow Global Technologies Inc PROCESS TO QUICKLY SELECT MICROBIAN HOST FOR THE IDENTIFICATION OF CERTAIN BETTER YIELDS AND / OR QUALITY IN EXPRESSION OF HETEROLOGICAL PROTEINS
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2692585A1 (en) 2007-07-03 2010-01-04 Amgen Inc. Measurement of protein using inclusion body dry weight
AU2008275229B2 (en) 2007-07-09 2014-11-06 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
US8629104B2 (en) 2008-02-18 2014-01-14 Jiangsu Hengrui Medicine Co. Ltd. G-CSF and water-soluble polymer conjugate
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
CN102223893B (en) 2008-07-22 2014-07-16 曼诺吉尼克斯公司 Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
EP3225248B1 (en) * 2008-07-23 2023-06-07 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
EA032727B1 (en) 2008-10-10 2019-07-31 Амген Инк. Fgf21 mutant proteolysis-resistant polypeptide and use thereof
CA2741065C (en) 2008-10-17 2017-04-25 Dana-Farber Cancer Institute, Inc. Muc-1 cytoplasmic domain peptides as inhibitors of cancer
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
JP2012525847A (en) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド FGF21 variants and uses thereof
PE20120358A1 (en) 2009-05-05 2012-04-26 Amgen Inc FGF21 MUTANTS AND USES OF THEM
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
US20130130283A1 (en) 2010-03-23 2013-05-23 Imba - Institut Fur Molekulare Biotechnologie Gmbh Methods for Identifying Inhibitors of the Type III Secretion System
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
ES2630031T3 (en) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. A chimeric pinniped-human leptin polypeptide with increased solubility
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
EP2897633B1 (en) 2012-09-18 2020-01-01 UTI Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
ES2756532T3 (en) 2013-03-15 2020-04-27 Gladiator Biosciences Inc Gla domains as routing agents
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
CA2988988A1 (en) * 2015-06-11 2016-12-15 Ambio Pharmaceuticals, Llc Pegylated granulocyte colony stimulating factor (gcsf)
US10947287B2 (en) * 2015-10-19 2021-03-16 Sandoz Ag DNA coding sequence for human G-CSF
CN108384747A (en) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 Express the Chinese hamster ovary celI serum free suspension cultural method of Rabies virus antibody
WO2021068074A1 (en) * 2019-10-08 2021-04-15 Zymeworks Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
CA3159912A1 (en) 2019-12-17 2021-06-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel g-csf mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (en) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd Processing method for chemical reaction information
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (en) * 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
EP0256843A1 (en) * 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
NO176799C (en) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA encoding a polypeptide, recombinant plasmid that encodes and can express a polypeptide and method for producing this polypeptide
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (en) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd HUMAN CRYSTALLINE GRANULOCYTE COLONY STIMULATION FACTOR AND ITS PRODUCTION.
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (en) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF)
JP3249147B2 (en) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0546124T4 (en) * 1990-08-29 2003-05-19 Inst Genetics Llc Multiple-domain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (en) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
CA2116533A1 (en) * 1991-08-30 1993-03-18 George J. Todaro Hybrid cytokines
JP2638359B2 (en) * 1991-11-26 1997-08-06 富士通株式会社 Constraint condition generator for molecular dynamics method
ATE195553T1 (en) * 1992-06-09 2000-09-15 Chiron Corp CRYSTALLIZATION OF M-CSF
ES2198416T3 (en) 1992-11-24 2004-02-01 G.D. SEARLE & CO. MULTIPLE MUTATION POLYPEPTIDES OF INTERLEUQUINA-3 (IL-3).
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
NZ320978A (en) 1995-10-05 2001-03-30 G Hematopoietic proteins and nucleic acid sequences encoding them
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
CA2234059A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel c-mpl receptor agonists
CA2234042A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP2001504689A (en) 1996-10-25 2001-04-10 ジー．ディー．サール アンド カンパニー Multifunctional chimeric hematopoietic receptor agonist
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
AU751498B2 (en) 1997-04-11 2002-08-15 G.D. Searle & Co. flt3 ligand chimeric proteins
AU6246599A (en) 1998-09-25 2000-04-17 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
ES2606840T3 (en) * 2001-10-10 2017-03-28 Ratiopharm Gmbh Remodeling and glycoconjugation of granulocyte colony stimulating factor (G-CSF)

Also Published As

Publication number Publication date
ES2382927T3 (en) 2012-06-14
NO20031497D0 (en) 2003-04-02
IL145994A0 (en) 2002-07-25
PT1482046E (en) 2012-06-06
US7381804B2 (en) 2008-06-03
IL124111A (en) 2002-09-12
NZ504840A (en) 2001-11-30
EP0965638A3 (en) 2000-02-23
KR960700341A (en) 1996-01-19
LV12642A (en) 2001-04-20
GR3034745T3 (en) 2001-02-28
IL124112A (en) 2006-12-10
FI123078B (en) 2012-10-31
CN1495197A (en) 2004-05-12
DE69425516T2 (en) 2001-06-13
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
HK1107356A1 (en) 2008-04-03
CN1118572C (en) 2003-08-20
CA2711007C (en) 2012-10-02
US20030171559A1 (en) 2003-09-11
JP2006137762A (en) 2006-06-01
EP0974655A3 (en) 2001-10-24
CA2153896C (en) 1999-01-12
JP2010059170A (en) 2010-03-18
EP0974655A2 (en) 2000-01-26
ATE553199T1 (en) 2012-04-15
ZA94568B (en) 1994-09-12
PT2345724E (en) 2013-08-22
IL125398A0 (en) 1999-03-12
ATE195552T1 (en) 2000-09-15
AU697451B2 (en) 1998-10-08
IL108446A0 (en) 1994-04-12
FI953593A0 (en) 1995-07-27
CA2381489A1 (en) 1994-08-04
DK1482046T3 (en) 2012-06-25
ES2422269T3 (en) 2013-09-10
EP1233065A1 (en) 2002-08-21
CN1132527A (en) 1996-10-02
EP1482046A2 (en) 2004-12-01
EP2345724B1 (en) 2013-07-03
CA2239360C (en) 2002-07-16
EP2345724A1 (en) 2011-07-20
JP2006096762A (en) 2006-04-13
DK0612846T3 (en) 2000-10-09
PT612846E (en) 2001-01-31
EP1482045A2 (en) 2004-12-01
CA2381489C (en) 2010-10-19
EP1482046B1 (en) 2012-04-11
AU6095794A (en) 1994-08-15
ES2150951T3 (en) 2000-12-16
US5581476A (en) 1996-12-03
EP0612846A1 (en) 1994-08-31
HK1009288A1 (en) 1999-05-28
CA2711007A1 (en) 1994-08-04
FI120769B (en) 2010-02-26
NZ314960A (en) 1999-01-28
NO20031497L (en) 2003-04-02
LU92265I2 (en) 2013-10-14
DK2345724T3 (en) 2013-09-30
US6632426B2 (en) 2003-10-14
US20050260154A1 (en) 2005-11-24
EP0890640A3 (en) 1999-03-24
US5790421A (en) 1998-08-04
NO952974L (en) 1995-09-28
NZ261765A (en) 1997-10-24
NO952974D0 (en) 1995-07-27
JP2004113243A (en) 2004-04-15
FI953593A (en) 1995-07-27
CA2153896A1 (en) 1994-08-04
US20010016191A1 (en) 2001-08-23
JP2009057368A (en) 2009-03-19
CN1495197B (en) 2013-01-16
US8058398B2 (en) 2011-11-15
KR100390338B1 (en) 2003-07-07
AU8197098A (en) 1998-10-15
JP2011207885A (en) 2011-10-20
DE69425516D1 (en) 2000-09-21
CN1970571B (en) 2013-07-10
EP0612846B1 (en) 2000-08-16
WO1994017185A1 (en) 1994-08-04
EP1482046A3 (en) 2005-01-05
EP0965638A2 (en) 1999-12-22
EP1482045A3 (en) 2004-12-29
IL108446A (en) 2003-01-12
CN1970571A (en) 2007-05-30
FI20090384A (en) 2009-10-21
NZ332188A (en) 2000-07-28
JPH08506018A (en) 1996-07-02
US6261550B1 (en) 2001-07-17
NO20093489L (en) 1995-09-28
IL145994A (en) 2010-12-30
KR100375274B1 (en) 2003-06-11
EP0890640A2 (en) 1999-01-13

Similar Documents

Publication Publication Date Title
CA2239360A1 (en) G-csf analog compositions and methods
EP0183350A3 (en) Dna endcoding human colony stimulating factor, peptide encoded thereby,vectors and transformed hosts containing such dna, and the production of all thereof
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
SI0866876T1 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
AU631312B2 (en) Muteins of the granulocyte colony stimulating factor (g-csf)
AU6312186A (en) Pharmaceutical composition for the treatment of leukopenia
AU6386786A (en) Human interferon-beta 2A and interferon-beta 2B; vectors containing genes coding for said interferons: cell lines producing same and use of said interferons as pharmaceuticals
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
CA2044468A1 (en) Canine granulocyte macrophage colony stimulating factor
CA2089111A1 (en) Smooth muscle mitogen and isolated dna coding therefor
AU7726287A (en) Process for the preparation of compounds comprising triazole or imidazole and tetrahydrofuran groups and new compounds used in the process
AU7516594A (en) Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo)
IL81023A (en) Human interferon-b2a, vectors containing genes coding for said interferon-b2a, cell lines producing same and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140127